Biotest AG - Company Profile
Powered by
All the data and insights you need on Biotest AG in one report.
- Save hours of research time and resources with
our up-to-date Biotest AG Strategy Report
- Understand Biotest AG position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Biotest AG (Biotest), a subsidiary of Grifols SA develops, manufactures and distributes biological medicines obtained from human blood plasma or manufactured through biotechnology methods. Its medicines are used in the areas of clinical immunology, haematology and intensive care medicine. The company operates its business through three operating segments, namely, Therapy, Plasma & Services, and Other Segments.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Biotest's R&D focuses on the development of new products in therapeutic areas including clinical immunology, haematology and intensive care medicine. It also focuses on developing its approved products for new indications. Biotest is actively involved in the continuous improvement and ongoing clinical development of its licensed products in the field of haematology. Additionally, the company is focused on expanding the range of clotting factors, which is of particular importance in the treatment of haematological conditions. Biotest has established itself as a leading authority in the field of immunology with its extensive proficiency in therapy involving polyvalent immunoglobulins (IVIg) for primary immune deficiencies and autoimmune diseases. The company is actively engaged in the development of medications targeting chronic progressive immune system disorders. One notable advancement is IgG Next Generation, a newly developed IVIg treatment designed specifically for addressing immunodeficiency and autoimmune diseases. Biotest is actively involved in the advancement of intensive care medicine, specifically through the development of trimodulin, a polyvalent antibody preparation. Trimodulin is uniquely formulated to include significant quantities of IgM and IgA antibodies alongside IgG, making it a promising treatment option for patients suffering from severe community-acquired pneumonia (sCAP) as well as those with severe COVID-19. The company’s pipeline products include CMV Hyperimmunglobulin in Phase III clinical trials indicated for the treatment of women who are infected with Cytomegalovirus (CMV); BT524 (fibrinogen) in Phase III indicated for the treatment of congenital fibrinogen deficiency and acquired fibrinogen deficiency. Biotest is investigating BT588 (Trimodulin) in Phase III clinical trials for the treatment of severe community-acquired pneumonia and severe COVID-19; and haemophilia A therapeutic (HAT) in pre-clinical studies for the treatment of haemophilia A. Biotest operates plasma collection centers in Germany, Czech Republic, and Hungary. It also seeks to work in partnership with other companies to develop its product candidates. In FY2022, the company incurred expenses of EUR49.9 million on its R&D, which as a percentage of sales, stood at 9.7%.
Business Segments
Overview
Include merchandise business and costs associated with either the Plasma and Services segment or Therapy segment.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Plasma & Services segment operates in the areas of plasma sales and toll manufacturing. Focuses on maximum utilization of its plasma production capacity.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Develops and produces immunoglobulins, clotting factors and albumins based on human blood plasma.It also includes the preclinical and clinical development of monoclonal antibodies for the treatment of multiple myeloma, rheumatoid arthritis and others. Major brands include Haemoctin, Haemonine, Vihuma, Cytotect, Hepatect, IgG Nex Generation, Varitect, Zutectra, Albiomin, Biseko, Cofact, Pentaglobin, Trimodulin, Anti SARS-CoV-2 hyperimmunoglobulin, Fovepta and Intratect. Intends to expand its vertical transmission prevention segment with the launch of Fovepta in new markets; and strives to maintain market share in post-transplant prophylaxis market.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer